Larimar Therapeutics Inc. Common Stock (LRMR)
Stock · NASDAQ · Health Care
$1.99as of 10/16/2026
Price chart
Active signals
LRMR Signal Track Record
How signals performed across all stocks →What LRMR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | +3.6% | 51% | September 11, 2026 |
| Bollinger Band Breakout | 25 | -0.5% | 48% | July 9, 2026 |
| Bollinger Band Breakdown | 22 | -2.5% | 50% | September 24, 2026 |
| 200-Day Moving Average TouchActive now | 13 | +2.4% | 62% | September 1, 2026 |
| Any 20-session window (baseline) | -0.5% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 71
- Website
- larimartx.com/
Fundamentals
- 1-day range
- $1.95$2.12
- Market cap
- $436.31M
- P/E (trailing)
- —
- P/E (forward)
- -1.88
- EPS (trailing)
- $-1.99
- Dividend yield
- —
- Beta
- 0.68
- Avg. volume
- 1.23M
- Dividend pay date
- May 29, 2020
Forecasts
10 analyst ratings
Larimar Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LRMRLarimar Therapeutics Inc. Common Stock$1.99▼ 0.25%Market cap $436.31MP/E —$2.06$6.42
- PRTAProthena Corporation plc Ordinary Shares$8.35▼ 1.76%Market cap $449.19MP/E —$7.73$11.8
- BNTCBenitec Biopharma Inc. Common Stock$8.11▼ 4.14%Market cap $451.07MP/E —$8.52$16.76
- ASMBAssembly Biosciences Inc. Common Stock$20.09▼ 2.33%Market cap $420.36MP/E 333.50$19.98$39.71
- RZLTRezolute Inc. Common Stock (NV)$3.58▼ 8.21%Market cap $452.57MP/E —$1.07$11.46
- PBYIPuma Biotechnology Inc Common Stock$9.83▼ 6.56%Market cap $413.30MP/E 20.62$4.58$10.5
- KMDAKamada Ltd. Ordinary Shares$7.76▼ 0.89%Market cap $411.88MP/E 20.30$6.55$9.35
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LRMR Larimar Therapeutics Inc. Common Stock | $436.31M | — | $1.99 | ▼ 0.25% | $2.06$6.42 |
| PRTA Prothena Corporation plc Ordinary Shares | $449.19M | — | $8.35 | ▼ 1.76% | $7.73$11.8 |
| BNTC Benitec Biopharma Inc. Common Stock | $451.07M | — | $8.11 | ▼ 4.14% | $8.52$16.76 |
| ASMB Assembly Biosciences Inc. Common Stock | $420.36M | 333.50 | $20.09 | ▼ 2.33% | $19.98$39.71 |
| RZLT Rezolute Inc. Common Stock (NV) | $452.57M | — | $3.58 | ▼ 8.21% | $1.07$11.46 |
| PBYI Puma Biotechnology Inc Common Stock | $413.30M | 20.62 | $9.83 | ▼ 6.56% | $4.58$10.5 |
| KMDA Kamada Ltd. Ordinary Shares | $411.88M | 20.30 | $7.76 | ▼ 0.89% | $6.55$9.35 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 5 Small Drug Stocks Poised to Benefit From a Biotech RecoveryYahoo · 9/14/2026
Insider Activity
Insider Actions →- Hamilton Thomas Edward · July 6, 2026 · Buy50.0K @ $3.34
- DEERFIELD MANAGEMENT COMPANY, L.P. · May 19, 2026 · Grant55.1K
- Truitt Joseph · May 19, 2026 · Grant55.1K
- Hamilton Thomas Edward · May 19, 2026 · Grant55.1K
- THOMAS FRANK E · May 19, 2026 · Grant55.1K
- SHERMAN JEFFREY W · May 19, 2026 · Grant55.1K
- LEFF JONATHAN S · May 19, 2026 · Grant55.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 87.44M
- Total value held
- $392.22M
- Institutional holders
- 157
- Unknown35.61M
- Unknown7.12M
- Unknown3.75M
- Unknown3.63M
- Unknown3.00M
- Unknown2.93M
- Unknown2.87M
- Unknown2.03M
- Unknown1.65M
- Unknown1.50M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Larimar Therapeutics Names John Harlow as President and COO
Larimar Therapeutics has appointed John Harlow as its new President and Chief Operating Officer, effective September 29. This leadership change is intended to strengthen the company's executive team. The stock is currently trading near its 52-week low, which provides context for this operational update.
Larimar Therapeutics Names John Harlow as President and COO. Larimar Therapeutics has appointed John Harlow as its new President and Chief Operating Officer, effective September 29. This leadership change is intended to strengthen the company's executive team. The stock is currently trading near its 52-week low, which provides context for this operational update.